Form 4: Avalo Therapeutics CMO Reports Stock Disposition

Chief Medical Officer Mittie Doyle disposed of 1,084 shares of Avalo Therapeutics common stock to cover tax obligations.

Summary

• Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc. (AVTX), reported the disposition of 1,084 shares of common stock.
• The transaction occurred on June 10, 2026, at a price of $13.10 per share.
• The disposition was executed to satisfy tax withholding obligations related to the vesting of equity awards.
• Following this transaction, the reporting person maintains beneficial ownership of 51,776 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a routine administrative action related to tax obligations rather than a discretionary sale.

Positives

• The reporting person continues to hold a significant position of 51,776 shares, indicating ongoing alignment with shareholder interests.

Negatives

• The transaction represents a reduction in the direct equity holdings of a key executive.

Risks

• Executive stock sales, even for tax purposes, can sometimes be perceived negatively by the market if interpreted as a lack of confidence in future performance.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine tax-related dispositions by executives are standard corporate practice and generally do not reflect a change in strategic outlook or internal sentiment regarding the company's clinical pipeline.

Comparison to Industry Standards

• The transaction follows standard SEC reporting requirements for executive equity compensation.
• The use of 'sell-to-cover' transactions is a common industry practice for managing tax liabilities associated with restricted stock unit vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related disposition.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Avalo Therapeutics, AVTX, Form 4, Insider Trading, Chief Medical Officer, Equity Compensation